Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Aug 2025 According to an INmune Bio media release, additional data from the MINDFuL trial was presented by a Key Opinion Leader, Dr. Sharon Cohen of the Toronto Memory Program, at the Alzheimer's Association International Conference (AAIC) on July 29th. This data is summarized in the forest plot below.
29 Jul 2025 According to an INmune Bio media release,a video detailing the additional findings from the Phase 2 MINDFuL trial will be published on the companys YouTube Channel following the conclusion of Alzheimers Association International Conference (AAIC) in Toronto, Canada.
24 Jul 2025 According to an INmune Bio media release, the company anticipates submitting a publication by mid-August of the MINDFuL Phase 2 study results.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com